According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...

The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold increase in cancer detection when added to standard screening tests for breast, ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

Walmart is the latest US retail pharmacy giant to announce its intention of disrupting the clinical trials category, with the launch of a new institute that pledges to increase and diversify community ...

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now expected to be down around $9 ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

Reimbursement authority NICE has said that Apretude (cabotegravir) can now be used as an alternative to daily oral PrEP pills ...

Lila Sciences' already impressive $235 million first round financing has continued to build and has now closed at $350 ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...